echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > What changes are taking place in the current pharmaceutical industry that cannot be ignored?

    What changes are taking place in the current pharmaceutical industry that cannot be ignored?

    • Last Update: 2020-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] for investors, it is very important to understand the current situation of the industry, keep track of the changes of the industry, so as to seize good investment opportunities Now, what changes are taking place in the pharmaceutical industry that cannot be ignored? In recent years, China's aging population is increasing According to public data, the proportion of the elderly in China will rise rapidly from 12% to 30% in 2018-2050 The aging is accompanied by the characteristics of the younger and the older, or further aggravates the aging degree of China's population structure Some experts predict that China will enter the stage of moderate aging in 2022 and severe aging in 2035 In this context, with the continuous upgrading of consumption level and the continuous improvement of health concept, China's clinical medical demand will continue to expand The industry believes that investment in the pharmaceutical industry needs to focus on this demographic trend The trend of fine management of medical insurance is more and more obvious In the context of the aging population in China, although the return on investment of the national social security fund is considerable, the pension gap is still increasing, and the existing pension security system is facing more severe challenges, which also makes the trend of fine management of medical insurance more and more obvious At present, medical reform policies such as generic drug consistency evaluation, volume purchase, DRGs, and consumables centralized purchase have been continuously promoted, and the drug pricing and market access system has been reshaped In addition, in the medical system, hierarchical diagnosis and treatment, new medical education and training mechanism are also gradually promoted The industry believes that the scientific nature of decision-making will be greatly improved Under the background of medical insurance control, the opportunity of structural investment in the pharmaceutical industry is more and more obvious On the one hand, with the consistency evaluation, the gradual normalization of the centralized purchase of drugs, and the promotion of the centralized purchase policy of medical consumables, the situation of the virtual high price of drugs and medical consumables will be improved Through the "cage for bird exchange", innovative drugs and devices as a whole will face better development space It is understood that the device is mainly divided into three parts: medical equipment, high value consumables and IVD At present, many high-value consumables market segments in China are small and scattered With the promotion of high-value consumables collection, it is conducive to improving the industry concentration There is a large space for localization and import substitution, among which the domestic consumables leader is expected to continue to benefit It is understood that some consumables are expensive in China and their penetration rate is not high, but under the background of high value consumables centralized mining, it is generally believed that there is a large space for equipment and consumables in the industry In order to further meet the needs of the rapid development of China's medical and health technology, the state health insurance bureau will gradually establish a reasonable determination and dynamic adjustment mechanism for medical service price items In the next three years, provinces will intensively adjust the price of medical services and improve the labor value of medical personnel At the same time, the decrease of charges for in vitro diagnosis accelerated the process of replacement of domestic reagents In addition, the gradual pilot promotion of DRGs policy will lead to the strategic reconstruction of ecosystem in the field of large health, with cost control as the core The growth rate of inpatient medical expenses may be controlled, and those hospitals that cannot actively adapt to the rules will be eliminated Some private capital medical institutions may gradually develop and grow because they pay more attention to cost control The industry believes that specialized pharmacies and third-party inspection and other industries will benefit At present, the industry believes that there are two main types of opportunities for investment in the pharmaceutical sector in recent years First, under the background of continuous improvement of industry concentration, the leading companies present the competitive situation of the strong and the constant The other is some innovative small companies, which can launch innovative products to better meet people's clinical needs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.